Treatment with statin before PCI intervention reduces MACE in patients with ACS

3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL, VS - Otavio Berwanger - São Paulo, Brasil

ACC 2018 Results of the SECURE-PCI trial showed a 28% decrease of MACE in patients treated with avorstatin compared to placebo before PCI intervention after ACS.

Educational information

This 3-minute education provides a summary of just presented scientific data, recorded during the ACC 2018. The objective is to provide a brief commentary and potential implications of these findings.

Faculty

Otavio Berwanger, MD, is a cardiologist and clinical epidemiologist in the Brazilian Clinical Research Institute in São Paulo, Brasil.

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.